Top Markets
Coin of the day
TFF Pharmaceuticals, Inc. TFF Pharmaceuticals, Inc.

TFF Pharmaceuticals, Inc.

TFFP
Clasificación en acciones #40710
Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals,... Operating as a clinical-stage biopharmaceutical company, TFF Pharmaceuticals, Inc., leverages its proprietary Thin Film Freezing (TFF) technology platform for the advancement and commercialization of therapeutic products across the United States and Australia. A primary emphasis is placed on creating inhaled dry powder formulations to address various pulmonary ailments and disorders. Its two leading drug candidates, both currently in Phase II clinical trials, include TFF Voriconazole Inhalation Powder, designed to combat invasive pulmonary aspergillosis, and TFF Tacrolimus Inhalation Powder, aimed at preventing lung transplant rejection. Beyond these, the company's pipeline features other dry powder products like a cannabidiol substance targeting various epilepsy syndromes, anxiety, insomnia, and pain; an Inhaled SARS-CoV2 Monoclonal Antibody for COVID-19 patients; Niclosamide Inhalation Powder, intended for human tapeworm infections and COVID-19; and a range of other vaccines. Strategic partnerships are also central to its operations, including a licensing arrangement with the University of Texas at Austin for inhaled dry powder drug development, a joint development pact with Augmenta Bioworks, Inc. for the inhaled SARS-CoV2 monoclonal antibody, and a broad licensing and collaboration agreement with UNION therapeutics A/S. Established in 2018, the company maintains its headquarters in Austin, Texas.
Precio por acción
$0.065
Última sincronización: 2025-01-10
Capitalización bursátil
$94.10K
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio TFF Pharmaceuticals, Inc. (TFFP)

Categoría

Ganancias de TFF Pharmaceuticals, Inc. (TFFP)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di TFF Pharmaceuticals, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de TFF Pharmaceuticals, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
- -
CH
- -
KR
$3.01B -
BE